Specialty Medications




Challenges and Opportunities in 2013



The Healthcare Dollar Flow

The Pharmacy Group

Improving Healthcare Performance





Key Milestones in US Healthcare

- 1973 Federal HMO Act Enacted
- 1983 DRG payments for hospitals
- 1993 PBMs bought by drug companies
- 2003 Medicare Modernization Act (Part D)
- 2013 Affordable Care Act implemented



What Are Specialty Medications?

A subset of medications that have some or all of the following characteristics:

- Expensive (over \$15,000 per year)
- Associated with complex clinical management
- Require close patient monitoring
- Produced through biotechnology mechanism
- Distributed through restricted provider network

Traditional/Specialty Medication Facts

- Total medication spend for the United States in 2010 was about \$300 billion
- Specialty medications account for 26% of total medication spend
- By 2014 specialty medications will comprise 40% of total medication spend
- About 1% of patients utilize specialty medications



What Do Payers Cover Now?



- Medical Benefits
 - Doctor visits
 - Hospitalization
 - Lab, X-ray, etc.



- Pharmacy Benefits
 - Traditional medications (pills/liquids)
 - Specialty medications (injectables/pills)




Not Covered





Specialty Medication Distribution Channels

Specialty



Pharmacy Benefit

Medical Benefit

Cost Management Challenges for both Pharmacy & Medical Benefit



Prescriber-Payer Matrix

FIGURE 1

The prescriber-payer matrix

					Patien	t						
					Prescrib	er						
Service providers	Logistics					Patient services						
Dispensers	Retail pharmacy			Specialty pharmacy provider		ong-term care	Hospital		VA/DoD	Infusion therapy provider		Clinic
Influencers	Group purchasing organization											
Distributors	Wholesa	ıler	Specialty pharmacy						rehousing Manufacturer directions		rer direc	
Controllers	Heal		Pharmacy bene manager		ts	Employer			Staff model			
Payers	Commercia	al Medica		е	Medicaid	٧	VA/DoD		Employers		Patients	
Regulators	HHS	HHS OIG		CMS F		0	SEC		FDA		States	
					Manufact	urer						

This figure depicts the many physical, financial, and transactional factors that manufacturers of specialty pharmaceuticals must take into consideration when they devise channels through which products will reach patients. Though manufacturers are in control of their channels, payers can influence them.

CMS=Center for Medicare & Medicaid Services, DoD=Department of Defense, FDA=U.S. Food and Drug Administration, FTC=Federal Trade Commission, HHS=Department of Health and Human Services, OIG=Office of the Inspector General, SEC=Securities and Exchange Commission, VA=Department of Veterans Affairs.


Source: Blue Fin Group 2012

TPG

Pharmacy Benefit-Dispensing of Specialty Products

FIGURE 2

Channels leading to dispensing of specialty products under the pharmacy benefit



Solid arrows connect links in the chains through which specialty products flow from manufacturer to patient, with a dispensing pharmacist being the penultimate link. Dashed black arrows indicate "white bagging" and "brown bagging" dispensing strategies that eliminate the buy-and-bill process, through which healthcare providers are reimbursed for their drug purchases under the medical benefit. Except for the office-administered products delivered via white- or brown-bagging, all the other specialty products flowing through these channels are administered by the patient or a caregiver. Dashed red lines indicate connections between reimbursement hubs, prescribers, and pharmacies. Hired and funded by manufacturers, hubs provide numerous services for providers, payers, and patients.

Source: Pembroke Consulting 2012



Specialty Medications

- Need to move from individual patient management to population health management
 - Appropriate use
 - Coverage policy
 - Evidence based medicine
 - Improve access
 - Patient safety



Specialty Medication Management Issues

- Claims Administration
 - Medical vs. pharmacy claims
- Cost Management
 - Physician office vs. pharmacy
 - Provider discounts (AWP, ASP, WAC)
 - Use of specialty preferred medication list
- Utilization Management
 Prior authorization and tracking



The Future

"This is like Deja Vu all over again."

Yogi Berra



TPG